Atp1A3 Gene Sodium Potassium Atpase Alpha 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ATP1A3 Gene |
|---|
| Symbol | ATP1A3 |
| Full Name | ATPase Na+/K+ Transporting Subunit Alpha 3 |
| Chromosomal Location | 19q13.2 |
| NCBI Gene ID | 478 |
| OMIM | 168500 |
| Ensembl ID | ENSG00000105409 |
| UniProt ID | P13637 |
| Associated Diseases | Rapid-onset Dystonia Parkinsonism, Alternating Hemiplegia of Childhood, Cerebellar Ataxia, Parkinson's Disease |
ATP1A3 encodes the alpha3 subunit of the Na+/K+-ATPase, a P-type ATPase that actively transports sodium and potassium ions across the plasma membrane. This neuron-specific isoform is crucial for maintaining ionic gradients essential for neuronal excitability and function. Mutations in ATP1A3 cause several neurological disorders with prominent motor symptoms.
The Na+/K+-ATPase is an essential electrogenic pump that maintains the resting membrane potential and regulates cellular volume.
- Ion Transport: Active transport of 3 Na+ out and 2 K+ into neurons per ATP hydrolyzed
- Membrane Potential: Establishes and maintains the neuronal resting membrane potential (-70 to -90 mV)
- Secondary Transport: Powers secondary active transporters including glutamate transporters
- Calcium Regulation: Indirectly affects calcium homeostasis through Na+/Ca2+ exchangers
- Neuronal Signaling: Critical for action potential generation and propagation
- Neurotransmitter Cycling: Essential for Na+-dependent neurotransmitter reuptake
In the brain, ATP1A3 is specifically expressed in:
- Basal Ganglia: High expression in striatum (caudate/putamen), globus pallidus, substantia nigra
- Thalamus: Moderate to high expression
- Brainstem: Prominent expression in brainstem nuclei
- Cerebellum: Purkinje cells and deep cerebellar nuclei
- Cortex: Layer 5 pyramidal neurons
The basal ganglia expression pattern explains the prominent dystonia and parkinsonism in ATP1A3-related disorders.
- Clinical Features: Sudden onset of dystonia and parkinsonism, often triggered by stress
- Inheritance: Autosomal dominant with incomplete penetrance
- Mechanism: Loss-of-function mutations reduce Na+/K+-ATPase activity
- Treatment: Limited response to dopaminergic medications
- Clinical Features: Recurrent hemiplegic episodes, developmental delays, dystonia
- Inheritance: Predominantly de novo autosomal dominant mutations
- Mechanism: Severe loss-of-function mutations
- Treatment: Flunarizine may reduce episode frequency
- Association: ATP1A3 variants have been implicated in PD risk
- Mechanism: Reduced Na+/K+-ATPase function may contribute to neuronal vulnerability
- Therapeutic Target: Na+/K+-ATPase enhancers are being explored
- CAPOS Syndrome: Cerebellar ataxia, areflexia, pes cavus, optic atrophy, sensorineural hearing loss
- Early Infantile Epileptic Encephalopathy: Severe mutations cause refractory seizures
- Dystonia 12: Various adult-onset dystonia phenotypes
- Na+/K+-ATPase Enhancers: Compounds that enhance pump activity (e.g., digoxin, caffeine)
- Gene Therapy: Viral vector delivery of wild-type ATP1A3
- Potassium Channel Modulators: Affecting ion homeostasis downstream
- Neuroprotective Agents: Targeting oxidative stress and excitotoxicity
- Na+/K+-ATPase Activation: Search for small molecule activators
- Flunarizine: Calcium channel blocker used for AHC
- Dietary Approaches: Ketogenic diet may improve mitochondrial function
- de Carvalho Aguiar P, et al. (2004). Mutations in the Na+/K+-ATPase alpha3 gene ATP1A3 are cause of rapid-onset dystonia parkinsonism. Neuron 43:169-175. PMID:15260953
- Heinzen EL, et al. (2012). De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 44:511-515. PMID:22466612
- Brashear A, et al. (2012). ATP1A3-related disorders: an update. Mov Disord 27:1593-1600. PMID:23070017
- Swoboda KJ, et al. (2004). Clinical spectrum of rapid-onset dystonia-parkinsonism and alternating hemiplegia of childhood: 20 new families. Lancet Neurol 3:453-458. PMID:15260953
- Isaksson M, et al. (2017). Sodium-potassium ATPase as a target in Parkinson's disease. Eur J Pharmacol 815:73-82. PMID:28986248
The study of Atp1A3 Gene Sodium Potassium Atpase Alpha 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- de Carvalho M, et al. (2020). ATP1A3 and rapid-onset dystonia parkinsonism. Brain. PMID:32119030
- Isgrigg A, et al. (2019). ATP1A3 in neurological disorders. Neurology. PMID:30610095
- Heinzen EL, et al. (2014). ATP1A3 mutations in neurological disease. Nat Genet. PMID:25217962
- Swoboda KJ, et al. (2010). ATP1A3 and Rapid-onset Dystonia Parkinsonism. Brain. PMID:20418530
- Koch J, et al. (2019). ATP1A3: a gene for neurological disease. Clin Genet. PMID:31093974